KDOQI (Kidney Disease Outcomes Quality Initiative)


NKF KDOQI GUIDELINES

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease


WORK GROUP BIOGRAPHIES

Pablo Aschner, MD, MSc, is Associate Professor and Head of the Endocrinology Unit at the Javeriana University School of Medicine and Scientific Sub-director at the Colombian Diabetes Association Clinical Research Center in Bogotá, Colombia. He specializes in Internal Medicine and Endocrinology and has a Master's degree in Clinical Epidemiology. He has served as a member of the World Health Organization Expert Advisory Panel on chronic degenerative diseases. He is also a past President of the Latin American Diabetes Association and the Latin American Diabetes Epidemiology Group. He also serves as a member of the International Diabetes Federation task force on Epidemiology. Dr Aschner has received compensation for lectures and/or consultations from AstraZeneca, Bayer, GlaxoSmithKline, Merck Sharp Dohme, and Sanofi-Aventis.

George L. Bakris, MD, is Professor of Medicine and Director of the Hypertension Unit at University of Chicago-Pritzker School of Medicine. He previously served as Director, Renal Research at Ochsner Clinic and Director of the Nephrology Fellowship Program at University of Texas, San Antonio. Dr Bakris currently serves as a National Kidney Foundation (NKF) representative for the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure (JNC 6 and JNC 7) and is a board-certified specialist in hypertension. He has received numerous National Institutes of Health (NIH) grants for clinical trials, including the African-American Study of Kidney Disease (AASK), Genetics of Hypertension (SCOR), and the K30 Clinical Trials Center awards. Dr Bakris has received compensation for lectures or consultations, research funds or grants from Abbott, AstraZeneca, ATLAS Foundation, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Kos Pharmaceuticals, Merck, Novartis, Sanofi-Aventis, and Walgreens.

Rudolf W. Bilous, MD, is Professor of Clinical Medicine and Honorary Consultant Physician at the University of Newcastle, UK. He received his fellowship from the Royal College of Physicians in London. From 1985 to 1987, he served as the Juvenile Diabetes Foundation International (JDFI) Post-Doctorate Fellow at the University of Minnesota and the NIH Fellow at Guy's Hospital in London from 1980 to 1982. He is currently serving as the Specialty Advisory Committee Chair for Endo/Diabetes of the Joint Committee for Higher Medical Training, as well as the Chairman of Professional Advisory Council Executive of Diabetes—UK (formerly the British Diabetic Association). Dr Bilous is also the Vice President of the European Diabetic Nephropathy Study Group, and his research interest has focused on diabetic nephropathy and clinical diabetes, including hypertension. Dr Bilous has received research grants from, or participated in clinical trials funded by AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Lilly Industries, Novo-Nordisk, Roche Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals.

M. Luiza Caramori, MD, MSc, PhD, is Assistant Professor of Medicine, Endocrinology Division, Department of Medicine at the University of Minnesota. She specialized in Internal Medicine (1992) and Endocrinology (1995) and has master's (1997) and doctorate (2001) degrees in diabetic nephropathy clinical research. From 1999 to 2002, she was a JDFI Post-Doctorate Fellow in the Division of Pediatric Nephrology at the University of Minnesota. Dr Caramori's research interest has focused on diabetic nephropathy relationships between kidney structure and function, genetic biomarkers of diabetic nephropathy, and the predictive value of albuminuria for diabetic nephropathy risk.

Jeffrey A. Cutler, MD, MPH, is Senior Scientific Advisor, Division of Epidemiology and Clinical Applications at the National Heart, Lung, and Blood Institute (NHLBI). He is involved with many NHLBI studies, including serving as a member of the Steering Committee for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial and the Executive Committee for the Trials of Hypertension Prevention. Dr Cutler has received several awards from the US Public Health Service, including 2 Commendation Medals, an Outstanding Service Medal, and a Meritorious Services Medal. His areas of research and special interest include the prevention and treatment of hypertension, other cardiovascular disease (CVD) prevention, clinical trials methods, and nutrition. Dr Cutler is affiliated with the American Heart Association (AHA), American Public Health Association, Society of Epidemiologic Research, Council on Epidemiology and Prevention—World Heart Federation, and American College of Preventive Medicine.

D. Jordi Goldstein-Fuchs, DSc, RD, currently is working as a clinical and research renal nutrition specialist in Sparks, Nevada. She is completing her 10th year as Editor of the Journal of Renal Nutrition. Dr Goldstein first became interested in kidney disease while studying for her Master's degree at the MGH Institute of Health Professions. Her research thesis was in the area of urea kinetic modeling, and the resulting publication was awarded the Mary P. Huddleson Award by the American Dietetic Association. After working as a renal dietitian for several years, Dr Goldstein returned to graduate school and received her Doctor of Science degree in Nutrition Science from Boston University. Her doctoral work was in the area of essential fatty acids and experimental kidney disease. She is the author of multiple scientific publications and book chapters. Dr Goldstein is a recipient of the 2003 Service Award from the NKF Council on Renal Nutrition. She is also a member of several nutrition and kidney societies, including the International Society of Renal Nutrition & Metabolism, the Council on Renal Nutrition of the NKF, and the American Dietetic Association. Dr Goldstein is a reviewer for several nutrition and nephrology journals, and she has received a research grant from Davita Inc.

Thomas H. Hostetter, MD, is a faculty member at Albert Einstein College of Medicine. He was a senior scientific adviser and director of the National Kidney Disease Education Program at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He was also Professor of Medicine at the University of Minnesota, where he was Director of the Renal Division in the Department of Internal Medicine for 15 years. He received his bachelor's degree in chemistry from Yale University. After graduating from Baylor College of Medicine, Dr Hostetter served his internship at Baylor and his residency at the Peter Bent Brigham Hospital. Following his nephrology fellowship at Brigham, he became a faculty member at Harvard Medical School. Dr Hostetter's major research interest is in the mechanisms of progressive kidney disease. He has served on several editorial boards, General Medicine B study section of the NIH, the Nephrology board of the American Board of Internal Medicine, the councils of the American and International Societies of Nephrology, and was president of the American Society of Nephrology from 1999 to 2000.

S. Michael Mauer, MD, is Professor of Pediatrics and Co-Director of Pediatric Nephrology at the University of Minnesota School of Medicine. He has more than 30 years of research interest in diabetic nephropathy, including diabetic nephropathy animal models, and human structural-functional relationships, pathophysiology, natural history, effects of pancreas transplantation, and clinical trials of glycemic control and renin-angiotensin system blockade. He is also working on diabetic nephropathy biomarkers and predictors. Dr Mauer has received research funds from Merck.

Mark E. Molitch, MD, is Professor of Medicine in the Division of Endocrinology, Metabolism, and Molecular Medicine at Northwestern University Feinberg School of Medicine. He received his fellowship at UCLA-Harbor General Hospital and is certified in Internal Medicine, as well as Endocrinology and Metabolism. Dr Molitch's areas of special interest are pathogenesis and treatment of diabetic nephropathy and pituitary tumors. In 1997, he received the Outstanding Physician Educator Award from the American Diabetes Association (ADA). Dr Molitch has received research funds, grants, or contracts from Abbott, Amgen, Bristol Myers Squibb, Eli Lilly & Co, Genentech, Ipsen, Joslin Research Foundation, Juvenile Diabetes Research Foundation, Novartis, Novo-Nordisk, Pfizer, Sanofi-Aventis, and Takeda Pharmaceuticals.

Andrew Narva, MD, is Director of National Kidney Disease Education Program at the National Institute of Diabetes and Digestive and Kidney Diseases. He has previously worked as a physician in Indian Health Service (IHS) since 1981 and served for 6 years as a general internist at the Keams Canyon (Arizona) and Albuquerque Service Units. Since completion of a nephrology fellowship in 1989, he has provided care to patients with kidney disease throughout New Mexico as the Albuquerque Area Nephrologist and has provided technical consultation and support to all IHS areas and to tribes as the Chief Clinical Consultant for Nephrology for IHS. He has served on the National Kidney and Urologic Diseases Advisory Board, the Renal Community Council of the US Renal Data System, and he is also a member of the Medical Review Board of End-Stage Renal Disease Network 15 and chair of the Minority Outreach Committee of the NKF. He is a member of the Steering Committee of the National Kidney Disease Education Program and the NKF Kidney Early Evaluation Program. Dr Narva is a graduate of Harvard Medical School and is board certified in Internal Medicine and Nephrology. He is an Associate Clinical Professor of Medicine at the University of New Mexico. In 2002, Dr Narva was recognized by the IHS National Council of Clinical Directors as Physician Leader of the Year and by the US Public Health Service (USPHS) as the Clinical Physician of the Year. In 2003, he received the USPHS Distinguished Service Medal, the highest recognition awarded to commissioned officers.

Robert G. Nelson, MD, PhD (Work Group Co-Chair), is a Staff Clinician at the NIDDK in Phoenix, Arizona. He received his medical degree and residency training in Internal Medicine and Public Health and General Preventive Medicine at Loma Linda University in California. He received an MPH at Harvard School of Public Health and a PhD in epidemiology from the University of California, Los Angeles. His research interests include complications of type 2 diabetes, and his primary research focus is diabetic nephropathy. He served previously as a Work Group member on the KDOQI™ Clinical Practice Guidelines for Chronic Kidney Disease (CKD): Evaluation, Classification, and Stratification. Dr Nelson has received study drugs from Merck for an ongoing clinical trial.

Marc A. Pfeffer, MD, PhD, is a Professor of Medicine, Harvard Medical School; Senior Physician Cardiovascular Division, Brigham and Women's Hospital; Fellow of the American College of Cardiology; and a member of 3 councils of the AHA (High Blood Pressure Research, Basic Science, and Clinical Cardiology). He serves on national and regional committees and prominent editorial boards. Dr Pfeffer's major interests are the pathophysiology of progressive cardiac dysfunction following myocardial infarction or systemic hypertension, and clinical management strategies for myocardial infarction and left ventricular dysfunction. He has served as the principal investigator of major clinical trials of angiotensin-converting enzyme inhibition postinfarction (SAVE and HEART) and as director of clinical centers for the Cholesterol and Recurrent Events (CARE) trial. Dr Pfeffer served as Co-Chair of the NIH/NHLBI-sponsored PEACE study, as well as co-chair of CHARM and principal investigator of VALIANT. Dr Pfeffer currently serves as the principal investigator of TREAT and Co-Chair of the ARISE trial. He has received research funds, grants, contracts or compensation for lectures, conferences or consultations from Amgen, AstraZeneca, AtheroGenics, Novartis and Sanofi-Aventis.

Michelle M. Richardson, PharmD, BCPS, is Clinical Associate Professor at Northeastern University's School of Pharmacy and Assistant Professor at Tufts University School of Medicine. She also serves on the Special and Scientific Staff of the William B. Schwartz, Division of Nephrology at Tufts-New England Medical Center. She received pharmacy residency training at the Warren G. Magnuson Clinical Center at the NIH, completed an Outcomes Research fellowship from Tufts-New England Medical Center, and is board certified in pharmacotherapy. Her special interests include pharmacotherapy in patients with kidney disease, health status, and patient satisfaction. Dr Richardson has received research funds, grants, or contracts from Amgen, Dialysis Clinic, and Ortho Biotech.

Mary Ann Sevick, ScD, RN, is Associate Professor in the School of Nursing at the University of Pittsburgh. She also serves as Affiliate faculty in the Center for Bioethics and Health Law at the University of Pittsburgh. She has published numerous articles in such scientific journals as the Journal of the American Dietetic Association, Peritoneal Dialysis International, American Journal of Nephrology, Preventive Medicine, American Journal of Preventive Medicine, and American Journal of Health Behavior. She has also presented at many national and international proceedings or conferences. She has participated in numerous NIH-funded studies involving behavior change interventions and is the principal investigator on studies examining the effectiveness of adherence enhancement interventions in people with type 2 diabetes and also in individuals receiving maintenance hemodialysis. Dr Sevick has received funding from the Paul Teschan Research Fund.

Michael Shlipak, MD, MPH, is Associate Professor of Medicine, Epidemiology and Biostatistics at the University of California, San Francisco. In 1999, he received the AHA Epidemiology Young Investigators Award, and in 2003 he became a Robert Wood Johnson Generalist Scholar and received the Paul Beeson Award from the American Federation for Aging Research. Dr Shlipak's areas of interest include kidney disease progression and CVD. Dr Shlipak is an unfunded co-investigator with Amgen.

Katherine R. Tuttle, MD (Work Group Co-Chair), is the Medical and Scientific Director of Research at Providence Medical Research Center, Spokane, WA. She received her medical degree and residency training in Internal Medicine at Northwestern University Medical School. She had fellowship training in Endocrinology and Metabolism at Washington University in St Louis, followed by a fellowship in Nephrology at the University of Texas Health Science Center in San Antonio. Her research interests are in the areas of diabetic kidney disease, hypertension, renal vascular disease, nutrition, and relationships between CKD and CVD. Dr Tuttle is Co-Chair of the Institutional Review Board—Spokane, which oversees the protection of human subjects in clinical research. She serves on the Board of Directors for the Washington Technology Center and the Advisory Board for the College of Sciences at Washington State University. Dr Tuttle has received the Outstanding Clinical Faculty award and is a Clinical Professor of Medicine at the University of Washington School of Medicine. She also holds an appointment as Professor of Basic Medical Sciences at Washington State University. She received the Woman of Distinction Award from the Girl Scouts for her achievements in science and mentorship for girls. Dr Tuttle is a fellow of the American Society of Nephrology and the American College of Physicians. She has received research funds, grants, or contracts from AstraZeneca, Eli Lilly, Merck, and Novartis.

Christoph Wanner, MD, is Professor of Medicine, Chief of the Division of Nephrology and Director of the Center of Clinical Research at the University Hospital, Würzburg, Germany. His areas of interest are metabolism, dyslipidemia, inflammation, and CVD in kidney patients and patients with Fabry disease. He has served as the principal investigator of the Deutsche Diabetes Dialyse Studie (4D) and is a steering committee member and central European coordinator of the Study of Heart and Renal Protection (SHARP). He serves as editor-in chief, subject editor, and member of the editorial review boards of many journals, including Kidney International, Nephrology Dialysis Transplantation, and Kidney & Blood Pressure Research. Dr Wanner currently serves a 3-year term as President of the NKF Germany and is a member of the Steering Committee of the German Society of Nephrology. Dr Wanner is a member of the KDIGO Board of Directors and the European Best Practice Guideline Hemodialysis Work Group. He has received research grants, served on advisory boards, and provided lectures for Amgen, Boehringer-Ingelheim, FMC, Gambro, Genzyme, Ortho Biotech, and Roche. Dr Wanner also is an investigator of the 4D involving atorvastatin, but he receives no honoraria.

 

Back to top | Main Page